LINCOLN PHARMA LTD Valuation
LINCOLN · Healthcare · Current price ₹612
Is LINCOLN PHARMA LTD undervalued?
DocStoX estimates the fair value of LINCOLN PHARMA LTD at ₹690 per share, versus the current market price of ₹612. That puts the stock about +12.8% below our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹392), Relative P/E (₹1,330), Graham floor (₹611). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹392 (bear) to ₹690 (base) to ₹1,330 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
LINCOLN PHARMA LTD trades at a P/E of 13.9x and a P/B of 1.7x, with a dividend yield of 0.3%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on LINCOLN PHARMA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.